Lecture Summary - ASCO 2022 NEOPRISM CRC: Neoadjuvant Pembrolizumab Stratified to Tumor Mutation Burden for High-Risk Stage 2/3 Deficient-MMR/MSI-H CRC

36 views
June 9, 2022
Comments 0
Login to view comments. Click here to Login